Meeting
2022 ASCO Annual Meeting
Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors.
Authors
Elio Adib
The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA
Elio Adib , Amin Nassar , Talal El Zarif , Neil Kale , Mehrdad Rakaee , Tarek H. Mouhieddine , Sarah Abou Alaiwi , Dory Freeman , Muhieddine Labban , Eli Akl , Robert I. Haddad , F. Stephen Hodi , Guru P. Sonpavde , Marios Giannakis , David A. Braun , Alexander Gusev , Toni K. Choueiri , Erin Overstreet , Everett Stone , David J. Kwiatkowski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2622)
DOI
10.1200/JCO.2022.40.16_suppl.2622
Abstract #
2622
Poster Bd #
277
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real-world outcomes of patients (pts) with malignant solid tumors treated with immune checkpoint inhibitors (ICI) in relation to smoking status: The SAKK 80/19 SMOKER study.
First Author: Tämer El Saadany
Poster
2023 ASCO Annual Meeting
Multi-center real-world data curation and assessment of tumor growth rate and overall survival in advanced NSCLC treated with PD-(L)1 immune checkpoint inhibitor therapy.
First Author: Chiharu Sako
Poster
2022 ASCO Annual Meeting
Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.
First Author: Miguel Angel Villalona-Calero